Clinical trial · Interventional
Diagnostic Evaluation of Viral Persistence in Cervical Cancer
Personalized, Scientifically Based Technologies in the Diagnosis and Treatment of SARS-CoV-2 as a Possible Cervical Cancer Risk Factor
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the diagnostic value of an electroacupuncture-based method for detecting viral persistence (human papillomavirus and SARS-CoV-2) in patients with cervical cancer. The study investigates whether persistent viral signatures can be identified through measurable electrodiagnostic responses at acupuncture points associated with organ systems affected by chronic viral infection. The goal is to assess the feasibility, reproducibility, and potential clinical relevance of this diagnostic approach in oncology patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Electroacupuncture | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic Group
- description
- Non-invasive diagnostic method assessing bioelectrical response patterns associated with viral markers in patients with cervical cancer.
- interventionNames
- Diagnostic Test: Electroacupuncture
Primary outcomes (1)
- measure
- Number of Participants With Bioelectrical Patterns Consistent With Viral Antigen Persistence
- timeFrame
- At enrollment (single diagnostic session)
- description
- Diagnostic assessment to identify bioelectrical response patterns associated with viral antigen persistence in cervical cancer patients using a non-invasive bioelectrical testing approach.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed cervical cancer (FIGO stage IIIA-IVA) * Age ≥21 years * ECOG performance status adequate for diagnostic procedures * Adequate organ function * Ability to provide informed consent Exclusion Criteria: * Poor renal function (elevated creatinine) * Significant liver dysfunction (elevated bilirubin or liver enzymes) * Severe cardiovascular or pulmonary disease * Pregnancy or breastfeeding * Severe mental illness or inability to provide informed consent * Known non-compliance or substance abuse
References
Publications (0)
Data not yet available